Debating the Science and Ethics of Synthetic Biology
News Nov 06, 2012
The panel, which includes Dr Helena Paul, Co-director of Econexus, Professor Robert Edwards, Chief Scientist of the Food and Environment Research Agency, Daisy Ginsberg, synthetic biology writer and commentator and Lionel Clarke, Chairman of the UK Synthetic Biology Roadmap Coordination Group, will take questions from the audience in Bristol and will respond to followers' questions on Twitter. The whole event will be webcast live and available to watch online.
For better or worse, synthetic biology is featuring more and more often in the media as scientists make new advances that attract headlines. News stories highlight some of the many ways in which synthetic biology could improve people's lives – from bio-energy and chemicals all the way through to drug delivery and regenerative medicine. But increased media attention also raises important issues around ethics, regulation and public acceptance.
The event – a collaboration between the Royal Society of Chemistry, the Biochemical Society, BioCentre and the University of Bristol – aims to stimulate discussion and inspire clear thinking about synthetic biology by bringing bring together senior members of the scientific community from industry and academia, along with policy makers to explore some of the questions and perceptions surrounding the subject.
Giant Viruses Invent Their Own GenesNews
Three new members have been isolated and added to the Pandoravirus family. This strange family of viruses, with their giant genomes and many genes with no known equivalents, surprised scientists when they were discovered a few years ago. This new study notes that pandoraviruses appear to be factories for new genes – and therefore new functions.
Therapeutic CRISPR Could Be Cancer RiskNews
Therapeutic use of gene editing with the so-called CRISPR-Cas9 technique may inadvertently increase the risk of cancer, according to a new study. Researchers say that more studies are required in order to guarantee the safety of these ‘molecular scissors’ for gene-editing therapies.